tetano
Editor, Senior Moderator
Vaccine. 2017 Feb 3. pii: S0264-410X(17)30088-9. doi: 10.1016/j.vaccine.2017.01.039. [Epub ahead of print]
[h=1]Microarray profile of the humoral immune response to influenza vaccination in breast cancer patients treated with chemotherapy.[/h] Wumkes ML[SUP]1[/SUP], van der Velden AM[SUP]2[/SUP], de Bruin E[SUP]3[/SUP], Meerveld-Eggink A[SUP]4[/SUP], Koopmans MP[SUP]5[/SUP], Rimmelzwaan GF[SUP]6[/SUP], Rijkers GT[SUP]7[/SUP], Biesma DH[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Patients treated with chemotherapy have an impaired response to influenza virus vaccination compared to healthy controls. Little is known about the broadness of the antibody response in these patients.
[h=4]METHODS:[/h] Breast cancer patients on FEC (5-fluorouracil, epirubicin and cyclophosphamide) chemotherapy regimens were vaccinated with influenza virus vaccine. Sera were obtained before and three weeks after vaccination. In addition to the determination of virus-specific antibody titres by hemagglutination inhibition assay, the broadness of the response was assessed by the use of a protein microarray and baseline titres were compared with an age-matched reference group.
[h=4]RESULTS:[/h] We included 38 breast cancer patients and found a wide variety in serum antibody response after vaccination. Patients with a history of influenza vaccination had higher pre-vaccination titres, which were comparable to the reference group. Increasing number of cycles of chemotherapy did not have a negative effect on influenza array antibody levels, nor on the HI antibody response.
[h=4]CONCLUSIONS:[/h] Overall there was a broad serum antibody response to the influenza virus vaccine in patients treated with chemotherapy for breast cancer.
Copyright ? 2017. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Antigen microarray; Breast cancer; Chemotherapy; Influenza vaccination; Profiling immune response
PMID: 28169075 DOI: 10.1016/j.vaccine.2017.01.039
[PubMed - as supplied by publisher]
[h=1]Microarray profile of the humoral immune response to influenza vaccination in breast cancer patients treated with chemotherapy.[/h] Wumkes ML[SUP]1[/SUP], van der Velden AM[SUP]2[/SUP], de Bruin E[SUP]3[/SUP], Meerveld-Eggink A[SUP]4[/SUP], Koopmans MP[SUP]5[/SUP], Rimmelzwaan GF[SUP]6[/SUP], Rijkers GT[SUP]7[/SUP], Biesma DH[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Patients treated with chemotherapy have an impaired response to influenza virus vaccination compared to healthy controls. Little is known about the broadness of the antibody response in these patients.
[h=4]METHODS:[/h] Breast cancer patients on FEC (5-fluorouracil, epirubicin and cyclophosphamide) chemotherapy regimens were vaccinated with influenza virus vaccine. Sera were obtained before and three weeks after vaccination. In addition to the determination of virus-specific antibody titres by hemagglutination inhibition assay, the broadness of the response was assessed by the use of a protein microarray and baseline titres were compared with an age-matched reference group.
[h=4]RESULTS:[/h] We included 38 breast cancer patients and found a wide variety in serum antibody response after vaccination. Patients with a history of influenza vaccination had higher pre-vaccination titres, which were comparable to the reference group. Increasing number of cycles of chemotherapy did not have a negative effect on influenza array antibody levels, nor on the HI antibody response.
[h=4]CONCLUSIONS:[/h] Overall there was a broad serum antibody response to the influenza virus vaccine in patients treated with chemotherapy for breast cancer.
Copyright ? 2017. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Antigen microarray; Breast cancer; Chemotherapy; Influenza vaccination; Profiling immune response
PMID: 28169075 DOI: 10.1016/j.vaccine.2017.01.039
[PubMed - as supplied by publisher]